more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.93 USD

+0.29 (0.46%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $63.85 -0.08 (-0.13%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

Top 33% (84 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates

by Zacks Equity Research Published on August 27,2020

The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.

Stock Market News for Aug 26, 2020

by Zacks Equity Research Published on August 27,2020

Benchmarks closed higher on Wednesday fueled by a rally in technology shares amid positive coronavirus vaccine trail news.

Moderna Stock Surges 260% YTD on Coronavirus Vaccine Progress

by Zacks Equity Research Published on August 27,2020

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. The vaccine is currently in phase III study.

biotechs

AstraZeneca Begins Coronavirus Antibody Combo Phase I Study

by Zacks Equity Research Published on August 26,2020

AstraZeneca's (AZN) AZD7442 is a combination of two coronavirus-neutralizing monoclonal antibodies, AZD8895 and AZD1061.

pharmaceuticals

5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks

by Sweta Killa Published on August 26,2020

While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.

Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study

by Zacks Equity Research Published on August 25,2020

Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.

biotechs

AstraZeneca Coronavirus Vaccine May Get FDA's Emergency Tag

by Zacks Equity Research Published on August 25,2020

AstraZeneca's (AZN)/Oxford's AZD1222 is in phase II/III study in the UK, Brazil and South Africa with a late-stage study due to start soon in the United States with 30,000 participants.

pharmaceuticals

Regeneron Gains on Coronavirus Treatment Development Efforts

by Zacks Equity Research Published on August 21,2020

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.

biotechs

Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa

by Zacks Equity Research Published on August 18,2020

Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.

biotechs

AstraZeneca (AZN) to Supply Coronavirus Vaccine in Europe

by Zacks Equity Research Published on August 17,2020

AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved.

pharmaceuticals

Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government

by Zacks Equity Research Published on August 14,2020

Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.

biotechs

Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine

by Sweta Jaiswal, FRM Published on August 13,2020

Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.

Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day

by Zacks Equity Research Published on August 13,2020

Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day

Implied Volatility Surging for Moderna (MRNA) Stock Options

by Zacks Equity Research Published on August 13,2020

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

MRNAPositive Net Change

biotechs

US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch

by Ritujay Ghosh Published on August 13,2020

The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.

Moderna Up on $1.5B Federal Funding for Coronavirus Vaccine

by Zacks Equity Research Published on August 12,2020

Moderna (MRNA) inks a deal with the U.S. government for supplying 100 million doses of mRNA-1273, its vaccine against COVID-19. Shares rise in pre-market trading.